Investors with Losses in Sarepta Therapeutics Have Class Action Lawsuit Opportunity

Sarepta Therapeutics Class Action Lawsuit: Investor Opportunity

Investors who have suffered considerable losses in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) are being invited to consider leading a class action lawsuit against the company. The law firm Robbins Geller Rudman & Dowd LLP has announced that those who purchased or acquired Sarepta securities between June 22, 2023, and June 24, 2025, have until Monday, August 25, 2025, to express their interest in becoming the lead plaintiff in this legal action.

Background of the Case

The lawsuit, identified as Dolgicer v. Sarepta Therapeutics, Inc., claims that Sarepta and its executives committed violations under the Securities Exchange Act of 1934. The biopharmaceutical company is primarily engaged in developing therapies aimed at treating Duchenne muscular dystrophy (Duchenne). One of their key products, ELEVIDYS, a gene therapy designed specifically for patients with Duchenne, is at the center of these allegations.

Allegations Against Sarepta

The complaint argues that throughout the aforementioned class period, Sarepta misled investors by failing to disclose critical information about ELEVIDYS. Specifically, the lawsuit asserts:
1. ELEVIDYS presented significant safety risks to patients.
2. The clinical trial protocols related to ELEVIDYS were inadequate for identifying severe side effects.
3. Adverse events resulting from the treatment were severe enough to necessitate the halting of patient recruitment and dosing in the clinical trials, inviting regulatory scrutiny and exacerbating risks surrounding the therapy's approvals.

Major Developments in the Case

On March 18, 2025, Sarepta announced a tragic incident where a patient treated with ELEVIDYS suffered acute liver failure, ultimately leading to death. This alarming report caused Sarepta's stock to plummet by more than 27% on the day the news broke. Following this, on April 4, 2025, the company revealed that European authorities requested an emergency meeting to review the incident, leading to additional stock declines.

The situation worsened on June 15, 2025, when Sarepta disclosed that a second patient had died from acute liver failure after receiving ELEVIDYS. This prompted further action from Sarepta, including the suspension of shipments for non-ambulatory patients and a pause in a key clinical study to comply with the U.S. Food and Drug Administration (FDA). The shareholders reacted negatively, resulting in a 42% decline in stock prices.

Finally, on June 24, 2025, the FDA issued a Safety Communication about the ongoing investigation into the risk of severe liver failure associated with ELEVIDYS, causing the stock to dip an additional 8% in response to the announcement.

The Role of Lead Plaintiff

The Private Securities Litigation Reform Act of 1995 allows investors who acquired Sarepta securities during the class period to seek the position of lead plaintiff in the lawsuit. This role typically involves representing the interests of all individuals in the class who have been impacted. The lead plaintiff will also have the authority to choose a legal team to handle the case.

Despite the opportunity to lead, it’s crucial for potential plaintiffs to understand that participating in the lawsuit does not depend upon becoming the lead plaintiff, and all investors may share in any recovery achieved.

About Robbins Geller

Founded in San Diego, Robbins Geller Rudman & Dowd LLP stands as a prominent legal firm representing investors in securities fraud and litigation concerning shareholders. The firm has made major strides in securing return on investments for clients, ranking consistently at the top in terms of monetary relief awarded. In 2024 alone, they successfully recovered over $2.5 billion for investors in related cases, reflecting their substantial expertise in the field.

Conclusion

Investors of Sarepta Therapeutics facing financial losses due to the alleged mishaps surrounding ELEVIDYS might want to explore this opportunity as a way to seek justice and potentially recover their losses. For further inquiries or to express interest in becoming involved, investors are encouraged to reach out to Robbins Geller or visit their official website for more details.